Gonadorelin
- Atc Codes:H01CA01#V04CM01
- CAS Codes:52699-48-6#33515-09-2#51952-41-1
- PHARMGKB ID:52699-48-6#33515-09-2#51952-41-1
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Kryptokur, Lutrelef; Belgium: HRF; Czech Republic: LHRH; France: LHRH, Lutrelef; Germany: Gonavet Veyx Depherelin, Kryptocur, LHRH, Lutrelef, Ovarelin, Relefact LH-RH; Greece: Relefact LHRH; Ireland: HRF; Italy: Kryptocur, Lutrelef; Luxembourg: HRF, Kryptocur; Netherlands: Crytocur, Relefact LH-RH; Poland: Relisorm L, Zyclomat pulse set-Lutrelef; Slovakia: Decapectyl; Sweden: Lutrelef; UK: HRF.
North America
Canada: Lutrepulse, Relisorm.
Asia
Japan: Hypocrine, LH-RH.
Drug combinations
Chemistry
Gonadorelin Acetate: C~55~H~75~N~17~O~13~ xC~2~H~4~O~2~ yH~2~O. Gonadorelin acetate is the diacetate salt or a mixture of mono- and diacetate hydrates. (1) Luteinizing hormone-releasing factor acetate hydrate; (2) 5-Oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosylglycyl-L-leucyl-L-arginyl-L-prolylglycinamide acetate hydrate. CAS-52699-48-6; CAS-33515-09-2 (gonadorelin)(1975).
Gonadorelin Hydrochloride: C~55~H~75~N~17~O~13~ 2HCl. Mw: 1255.21. 5-Oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosylglycyl-L-leucyl-L-arginyl-L-prolylglycinamide hydrochloride. CAS-51952-41-1 (1975).
Pharmacologic Category
Gonadotropins. Diagnostic Agents; Pituitary Function. Gonadotrophic Hormone. (ATC-Code: H01CA01; V04CM01).
Mechanism of action
Stimulates release of luteinizing hormone (LH) from anterior pituitary gland.
Therapeutic use
Evaluation of functional capacity and response of gonadotrophic hormones. Evaluation of abnormal gonadotropin regulation as in precocious puberty and delayed puberty. Treatment of primary hypothalamic amenorrhea. Treatment of one-and two-sided undescended testicles.
Pregnancy and lactiation implications
Unknown whether drug is excreted in breast milk (use caution).
Unlabeled use
Contraindications
Hypersensitivity to gonadorelin or any component of the formulation. Women with any condition that could be exacerbated by pregnancy. Patients with ovarian cysts or causes of anovulation other than those of hypothalamic origin. Any condition that may be worsened by reproductive hormones.
Warnings and precautions
Diluent for injection contains benzyl alcohol (large amounts associated with «gasping syndrome» in neonates). Hypersensitivity and anaphylactic reactions occurred following multiple-dose administration. Use with caution in women in whom pregnancy could worsen pre-existing conditions (e.g. pituitary prolactinemia). Multiple pregnancy possible.